Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 2/2010

01-04-2010 | Short Research Report

Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database

Authors: Vera Vlahović-Palčevski, Monja Gantumur, Nives Radošević, Goran Palčevski, Robert Vander Stichele

Published in: International Journal of Clinical Pharmacy | Issue 2/2010

Login to get access

Abstract

Objective: To illustrate the best approach to accurate representation of temporal evolution of drug consumption, when confronted with changes over time in the Defined Daily Dose (DDD) measurement unit. Method: As an example, drug consumption (2001–2005) at the University Hospital Rijeka was expressed with the corresponding DDD in each year; and with the DDD value of the last year of the observation time window. By visual appraisal, results with both methods were compared with the graph of drug consumption trends expressed in physical units (mg, IU, etc.). Results: Of 20 drugs for which the DDD value has changed in the 5 year period, 5 were used in Rijeka hospital: erythropoietin parenteral, budesonide nasal spray, repaglinide oral, amoxicillin with clavulanic acid parenteral, and fentanyl transdermal. Graphs for individual drugs with the year by year method showed artificial jerks in the years proceeding the year of DDD change. Representation of total hospital consumption did not differ notably with the two methods. Conclusion: Drug consumption data should be calculated with the latest DDD value in the time window. The policy of the World Health Organisation to keep changes to the system of DDD to a minimum should be continued.
Literature
2.
go back to reference Rønning M. Coding and classification in drug statistics—from national to global application. Nor J Epidemiol. 2001;1(1):37–40. Rønning M. Coding and classification in drug statistics—from national to global application. Nor J Epidemiol. 2001;1(1):37–40.
3.
go back to reference Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Ronning M, Vander Stichele RH. Drug utilization research. In: Hartzema AG, Tilson HH, Chan KA, editors. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Wittheny; 2008. ISBN 978-0-929375-30-4. Wettermark B, Vlahovic-Palcevski V, Salvesen Blix H, Ronning M, Vander Stichele RH. Drug utilization research. In: Hartzema AG, Tilson HH, Chan KA, editors. Pharmacoepidemiology and therapeutic risk management. Cincinnati: Harvey Wittheny; 2008. ISBN 978-0-929375-30-4.
4.
go back to reference World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO; 2009. World Health Organisation Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Oslo, Norway: WHO; 2009.
5.
go back to reference WHO Collaborating Centre for Drug Statistics methodology. ATC Index with DDD’s. Oslo: WHO; 2001. WHO Collaborating Centre for Drug Statistics methodology. ATC Index with DDD’s. Oslo: WHO; 2001.
6.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2002. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2002.
7.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2003. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2003.
8.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2004. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2004.
9.
go back to reference WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2005. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index with DDD’s. Oslo: WHO; 2005.
10.
go back to reference Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17(1):20–4.CrossRefPubMed Natsch S, Hekster YA, de Jong R, Heerdink ER, Herings RM, van der Meer JW. Application of the ATC/DDD methodology to monitor antibiotic drug use. Eur J Clin Microbiol Infect Dis. 1998;17(1):20–4.CrossRefPubMed
11.
go back to reference Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf. 2002;11(6):447–53.CrossRefPubMed Heerdink ER, Urquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf. 2002;11(6):447–53.CrossRefPubMed
12.
go back to reference Stolk P, Heerdink ER, Leufkens HG. Changes in the defined daily dose; YP2D6/CYP3A metabolism as an indicator for dose-setting problems. Eur J Clin Pharmacol. 2005;61(3):243–6.CrossRefPubMed Stolk P, Heerdink ER, Leufkens HG. Changes in the defined daily dose; YP2D6/CYP3A metabolism as an indicator for dose-setting problems. Eur J Clin Pharmacol. 2005;61(3):243–6.CrossRefPubMed
Metadata
Title
Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database
Authors
Vera Vlahović-Palčevski
Monja Gantumur
Nives Radošević
Goran Palčevski
Robert Vander Stichele
Publication date
01-04-2010
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 2/2010
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-010-9366-0

Other articles of this Issue 2/2010

International Journal of Clinical Pharmacy 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.